HR Execs on the Move


 
VisionGate, Inc., is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Alan Nelson
Founder, Chairman and Chief Executive Officer Profile

Similar Companies

LA Habilitation House

LA Habilitation House is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enzyvant

Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.

Gel-Del

Gel-Del is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

West Pharmaceuitcals

West Pharmaceuitcals is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea`s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families.